Regarding “challenges of endovascular tube graft repair of thoracic aortic aneurysm: midterm follow-up and lessons learned”  by Verdant, Alain
The current criteria for duplex diagnosis of perforator incom-
petence are poorly defined, creating many limitations both in
investigation and in treatment. Perforator vessels in certain limbs
are useful for drainage and cannot simply be considered pathologic
perforating veins. Careful assessment by color Doppler scan of
inward flow during muscular diastole could correctly identify the
perforators to disconnect and those to save because, as we should
not forget, the aim of surgery in patients with chronic venous
insufficiency is to improve venous emptying, not just to indiscrim-
inately remove veins!
Paolo Zamboni, MD
University of Ferrara
Ferrara, Italy
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Reply
We read with interest Dr Zamboni’s letter concerning our
article. Although Dr Zamboni writes that his interpretation of our
results differs from our discussion, we believe there are more
similarities than differences. We agree that it is critical to develop a
better classification system for perforator veins than the one we
have now. Currently, perforator veins are classified as either com-
petent, implying normal function, or incompetent, implying abnor-
mal function. Unfortunately, the criteria for incompetence varies
significantly in the literature and is not based on the hemodynamic
significance of outward flow in the examined vein. We need to
develop a system that allows us to identify various degrees of
abnormality in these veins, and this may better direct us in thera-
peutic choices.
We also agree that many perforators demonstrate bidirectional
flow without causing venous dysfunction. The suggested study of
perforators during muscular contraction and relaxation may yield
further insight into normal patterns of flow. We believe that the
work of Delis et al1 is an important start in identifying categories of
perforator dysfunction. Through these initiatives, hopefully we can
develop a better understanding of which perforators are truly
pathologic versus those that demonstrate reflux but are hemody-
namically insignificant. An excellent tool has been developed for
perforator ligation (SEPS), but more must be done to determine
the optimal situations in which it should be utilized.
William Marston, MD
Robert Mendes, MD
Division of Vascular Surgery
University of North Carolina School of Medicine
Chapel Hill, NC
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Regarding “Challenges of endovascular tube graft
repair of thoracic aortic aneurysm: Midterm follow-
up and lessons learned”
Dr Marin and his colleagues have reported an extensive expe-
rience of 84 aneurysms of the descending thoracic aorta treated
with an endovascular prosthesis and have clearly established its
poor performance: a 38% major procedure–related or device-
related complication rate and a 15% attachment failure rate (J Vasc
Surg 2003; 38:676-83). At 40 months, the overall mortality is 33%
and the rate of rupture, type I endoleak, or type III endoleak is
26%. Hopefully their surgical leadership will serve as an inspiration
to question the widespread utilization of an irrational method of
thoracic aortic aneurysm exclusion.
These results are not surprising and are consistent with the
mode of intraluminal fixation against the aortic wall by lateral
pressure, excluding any feasibility of prosthesis anchorage to the
adventitial layer of the aorta. The addition of hooks with the
potential hazards of esophageal perforation will never replace a
precise and blood tight atraumatic suture line.
The firm advocates of this new technology have underesti-
mated a fundamental principle for long-term successful implanta-
tion of an aortic prosthetic graft: the adventitia mostly made of
strong collagen fibers and assuring 60% of the tensile strength of
the aortic wall1 should be circumferentially included into a full
thickness host aorta-graft anastomosis. Any technique of graft
insertion in which the adventitia is either partially or completely
excluded is doomed to failure. This has been illustrated in the past
with two open techniques already abandoned many years ago: the
inclusion technique with a 25% incidence of false aneurysms2 and
the intraluminal sutureless prosthesis prone to migration.3
Two other problems have already been addressed by other
authors:
1. The fatigue of a very complex assembling made of a metallic
frame and a thin Dacron fabric will likely reproduce into a single
device the structural failure encountered with both cardiac valve
and Dacron prosthesis development over the past 50 years.4
2. The unavoidable poor tissue incorporation of an implant de-
ployed inside a dead space between the graft and the aorta with
persistent leakage of blood.5
Any standard open surgical procedure with comparable poten-
tial hazards and such alarming results would be seriously ques-
tioned by most of us and certainly not considered for the treatment
of young patients with acute or chronic traumatic aneurysms. I
have already expressed the opinion that these patients should be
referred to highly specialized centers for aortic surgery equipped
with fully trained personnel and optimal methods of organ protec-
tion.6 The major lesson to be learned from the excellent study of
Marin and colleagues is that the faithful compliance with basic
principles that have guided open cardiovascular techniques should
be also the rule for future development of less invasive techniques.
At this point of development, this inadequate technique of aneu-
rysm exclusion should be submitted to more vigorous experimen-
tal investigation and, at the very least, its clinical use reduced to a
strict minimum.
Alain Verdant, MD FRCS (C)
Chief of Vascular Surgery
Hoˆpital du Sacre´-Coeur de Montre´al
University of Montre´al
Montre´al, Que´bec, Canada
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Reply
We appreciate Dr Verdant’s comments regarding our recent
article describing our experience with endovascular stent graft
repair of thoracic aortic aneurysms. There are a few comments we
would specifically like to address.
Dr Verdant states that we have clearly established the “poor
performance” of this technology, implying that the 33% mortality
at 40 months is aneurysm related. This is incorrect. As is clearly
stated in the article, 6 deaths were attributable to aneurysm-related
causes. The rest were from underlying comorbid medical illnesses.
With regards to the Type I endoleak rate, we have adopted a more
liberal approach to performing combined open and endovascular
repairs of thoracic aneurysms. Since the time of publication, we
have enrolled 18 more patients in our protocol, all using the Talent
device. Of these 18 patients, 7 had their stent graft as the second
stage of an elephant trunk repair. The results in these 18 patients
have been heartening. We achieved primary clinical success in 17;
in 1 patient, we were unable to deliver the device due to aortic
tortuosity. There were 2 mortalities in this cohort: 1 from infective
endocarditis which was present at the time of initial presentation,
and 1 from a ruptured infrarenal aneurysm. There were no major
procedure-related morbidities. There were no thoracic aneurysm–
or device-related deaths. There were no Type I or Type III
endoleaks.
We agree wholeheartedly with Dr Verdant’s sentiment that
these cases should be done in “highly specialized centers for aortic
surgery equipped with fully trained personnel and optimal meth-
ods of organ protection.” As a matter of fact, our multidisciplinary
team includes a group of cardiac surgeons with extensive experi-
ence in open thoracic aneurysm repair. The cases are reviewed as a
group, and the most appropriate course of therapy is decided upon.
Thoracic stent-graft technology is still very much in evolution,
and we recognize that it is still investigational. One of the goals of
our article was to bring to light the limitations of current technol-
ogy. However, one should be careful not to “throw out the baby
with the bathwater.” Dr Verdant states that any “technique of graft
insertion in which the adventitia is . . . excluded is doomed to
failure.” Clinical data clearly suggests otherwise. The evolving
experience with endovascular stent-graft repair of infrarenal ab-
dominal aortic aneurysms has shown us that endoluminal aneu-
rysm exclusion results in a durable and safe repair with decreased
morbidity in properly selected patients.1 We feel confident that
with improvements in patient selection, device delivery systems,
and stent-graft design, the same will be true for the thoracic aorta.
The analogy can be made to the evolution of the prosthetic
cardiac valve, a process that took more than 15 years. Think how
many people would not be alive today if the development process
had been abandoned because of early failures.
Sharif Ellozy, MD
Alfio Carroccio, MD
Michael L. Marin, MD
Division of Vascular Surgery
David Spielvogel, MD
Department of Cardiothoracic Surgery
Mount Sinai Medical Center
New York, NY
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Regarding “Randomized trial and local biological
effect of autologous platelets used as adjuvant therapy
for chronic venous leg ulcers”
We read with the greatest interest the paper recently published
by Senet et al (J Vasc Surg 2003;38:1342-8). We appreciated the
very professional way used to assess the in vivo and in vitro capacity
(or incapacity) for platelet concentrate to enhance healing of
chronic ulcers. However, their results are quite different from our
own.
We have used platelet gel in clinical practice since 2000.
Platelet gel is a semisolid product obtained by activating autolo-
gous platelet concentrates with an autologous thrombin precursor
obtained by recalcification of autologous plasma. We obtain autol-
ogous platelets by processing either tubes or blood bag–collected
blood according to the necessary platelet gel volume or patient
conditions. Fresh or cryopreserved platelets are interchangeably
used, platelet-derived growth factors being quite thermostable.1,2
Whichever the blood collection system—tube differential centrif-
ugation or buffy-coat derived platelets as described by Senet et
al—we resuspend platelets in autologous plasma at the final con-
centration of 1-2 10/mL. So two main differences exist between
Senet et al’s platelet preparation and ours: we resuspend platelets in
fresh autologous plasma instead of saline, and the final platelet
concentration in our product actually is two to four times more
concentrated.
Senet et al treated lesions with 107 platelets/cm2. We treat
lesions with platelet gel containing 0.3-0.4  10 platelets/cm,
which is approximately 40 times the platelet amount used by Senet
and colleagues. Finally, we dress ulcerative lesions once per week
instead of 3 times per week.
In vitro experiments have shown that proliferation of human
fibroblast is strongly enhanced by addition of crude platelet lysate
to the culture medium. Proliferation rate is dose and time depen-
dent. The proliferation level is maximal between culture day 7 and
11. In our in-vitro experiments the proliferation rate was clearly
dose dependent, from 5% to 30% (platelet lysate/culture medium,
v/v considering 0% no addition of platelet lysate) (Fig). All of this
taken together may explain why Senet and colleagues obtained
negligible results in vivo and in vitro, in spite their highly profes-
sional experimental trial, while in our hands more than 85% of
patients respond to treatment and the healing time is roughly
halved.
We are confident that Senet and colleagues did not obtain
noticeable results either in vivo or in vitro simply because they used
platelet concentrates under the limit of biological activity of
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